Clinical Development Of Solasias First Drug Initiated
In Japan - Clinical Trials Also Planned For China

Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced initiation of a Phase 1 study of SP-01 (long-acting transdermal granisetron patch; brand name: Sancuso®) in Japanese[...]

Read The Full Article:
http://feedproxy.google.com/~r/zampbioworld/iblI/~3/1yu0SAUFA74/18997

Add to del.icio.us

Digg this

Post to Furl

Add to reddit

Add to myYahoo!